1h Free Analyst Time
The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.Speak directly to the analyst to clarify any post sales queries you may have.
The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.
SEGMENT ANALYSIS
- Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
- The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
- Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.
Market Segmentation by Drug Class
- Corticosteroids
- Kinase Inhibitors
- Calcineurin Inhibitors
- TNF-Alpha Inhibitors
- Other Class of Drugs
Market Segmentation by Treatment Type
- GVHD Prophylaxis
- Chronic GVHD
- Acute GVHD
Market Segmentation by Gender Type
- Males
- Females
GEOGRAPHIC ANALYSIS
- The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.
Market Segmentation by Geography
- North America
- US
- Europe
- France
- Germany
- Italy
- UK
- Spain
- APAC
- China
- Japan
VENDOR ANALYSIS
- With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.
Key Players
- Incyte
- Pharmacyclics
- Bristol-Myers Squibb
- JCR Pharmaceuticals Co., Ltd.
- Takeda Pharmaceutical Co Ltd (Takeda)
- MaaT Pharma
- XeniKos
- Medac GmbH
- Mesoblast
- Kadmon
- Jazz Pharmaceuticals
- Gsk
- Novartis
- Syndax Pharmaceuticals Inc
Other Prominent Vendors
- Neovii
- ElsaLys Biotech
- Mallinckrodt
- Regimmune
- Roche
- Altrubio
- CTTQ
- Equillium
- Janssen (johnson & johnson)
- ASC Therapeutics
- MSD
- Genentech
- Sun Pharma
- Mink Therapeutics
- Pluristem
The Report Covers The following details:
- Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
- Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
- Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
- Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
- Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
- In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
- Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
- Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
- Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
- Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
- Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space
Table of Contents
Chapter - 1 Gvhd Overview
Chapter - 2 Gvhd Epidemiology & Overview
Chapter - 3 Gvhd Market Size & Overview
Chapter - 4 Gvhd Marketed Drugs Overview
Chapter - 5 Gvhd Pipeline Drugs Overview
Chapter - 6 Gvhd Clinical Trials Overview
Chapter - 7 Gvhd Market Dynamics
Chapter - 8 Gvhd Competitive Landscape
Chapter - 9 Gvhd Miscellaneous
Chapter - 10 Appendix
Companies Mentioned
- Incyte
- Pharmacyclics
- Bristol-Myers Squibb
- JCR Pharmaceuticals Co., Ltd.
- Takeda Pharmaceutical Co Ltd (Takeda)
- MaaT Pharma
- XeniKos
- Medac GmbH
- Mesoblast
- Kadmon
- Jazz Pharmaceuticals
- Gsk
- Novartis
- Syndax Pharmaceuticals Inc
- Neovii
- ElsaLys Biotech
- Mallinckrodt
- Regimmune
- Roche
- Altrubio
- CTTQ
- Equillium
- Janssen (johnson & johnson)
- ASC Therapeutics
- MSD
- Genentech
- Sun Pharma
- Mink Therapeutics
- Pluristem
Methodology
Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.
Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.
LOADING...
